ilginatinib   Click here for help

GtoPdb Ligand ID: 7839

Synonyms: NS-018 | NS018
PDB Ligand
Compound class: Synthetic organic
Comment: Ilginatinib (NS-018) is a potent and highly selective JAK2 inhibitor. It has an ATP-competitive mode of action. The chemical structure shown here was rendered from the chemical name provided in [1]. The inhibits some Src family kinases in addition to JAK2 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 80.55
Molecular weight 389.18
XLogP 4.14
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(cc1)C(Nc1nc(Nc2cnccn2)cc(c1)c1cnn(c1)C)C
Isomeric SMILES Fc1ccc(cc1)[C@@H](Nc1nc(Nc2cnccn2)cc(c1)c1cnn(c1)C)C
InChI InChI=1S/C21H20FN7/c1-14(15-3-5-18(22)6-4-15)26-19-9-16(17-11-25-29(2)13-17)10-20(27-19)28-21-12-23-7-8-24-21/h3-14H,1-2H3,(H2,24,26,27,28)/t14-/m0/s1
InChI Key UQTPDWDAYHAZNT-AWEZNQCLSA-N
References
1. Nakaya Y, Shide K, Naito H, Niwa T, Horio T, Miyake J, Shimoda K. (2014)
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.
Blood Cancer J, 4: e174. [PMID:24413068]
2. Nakaya Y, Shide K, Niwa T, Homan J, Sugahara S, Horio T, Kuramoto K, Kotera T, Shibayama H, Hori K et al.. (2011)
Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.
Blood Cancer J, 1 (7): e29. [PMID:22829185]
3. Verstovsek S, Talpaz M, Ritchie E, Wadleigh M, Odenike O, Jamieson C, Stein B, Uno T, Mesa RA. (2017)
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
Leukemia, 31 (2): 393-402. [PMID:27479177]